Public Employees Retirement Association of Colorado decreased its position in Zoetis Inc (NYSE:ZTS) by 0.1% in the third quarter, Holdings Channel reports. The firm owned 1,518,487 shares of the company’s stock after selling 1,584 shares during the period. Zoetis accounts for 1.2% of Public Employees Retirement Association of Colorado’s investment portfolio, making the stock its 17th largest holding. Public Employees Retirement Association of Colorado’s holdings in Zoetis were worth $189,188,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently made changes to their positions in ZTS. Nuveen Asset Management LLC boosted its holdings in shares of Zoetis by 40,874.9% in the second quarter. Nuveen Asset Management LLC now owns 7,078,826 shares of the company’s stock valued at $803,376,000 after purchasing an additional 7,061,550 shares during the period. Stonehage Fleming Financial Services Holdings Ltd purchased a new stake in shares of Zoetis during the second quarter valued at $133,113,000. Bank of New York Mellon Corp grew its holdings in shares of Zoetis by 9.5% during the second quarter. Bank of New York Mellon Corp now owns 4,420,261 shares of the company’s stock valued at $501,654,000 after buying an additional 383,799 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Zoetis by 1.0% during the second quarter. Vanguard Group Inc. now owns 36,765,577 shares of the company’s stock valued at $4,172,526,000 after buying an additional 346,167 shares during the last quarter. Finally, Natixis grew its holdings in shares of Zoetis by 147.1% during the second quarter. Natixis now owns 547,078 shares of the company’s stock valued at $62,088,000 after buying an additional 325,661 shares during the last quarter. Hedge funds and other institutional investors own 89.95% of the company’s stock.
NYSE:ZTS traded down $3.17 during mid-day trading on Friday, hitting $117.86. The company’s stock had a trading volume of 3,757,845 shares, compared to its average volume of 2,125,332. The business’s fifty day moving average is $125.46 and its two-hundred day moving average is $116.48. The company has a debt-to-equity ratio of 2.74, a current ratio of 4.17 and a quick ratio of 2.87. Zoetis Inc has a 1 year low of $78.90 and a 1 year high of $130.20. The stock has a market cap of $57.43 billion, a price-to-earnings ratio of 37.65, a PEG ratio of 2.98 and a beta of 0.88.
The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Tuesday, October 22nd will be paid a dividend of $0.164 per share. This represents a $0.66 annualized dividend and a dividend yield of 0.56%. The ex-dividend date is Monday, October 21st. Zoetis’s payout ratio is currently 21.09%.
In other news, EVP Clinton A. Jr. Lewis sold 6,123 shares of the stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $128.62, for a total transaction of $787,540.26. Following the sale, the executive vice president now directly owns 39,141 shares of the company’s stock, valued at approximately $5,034,315.42. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Kristin C. Peck sold 11,500 shares of the stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $123.22, for a total transaction of $1,417,030.00. Following the sale, the executive vice president now directly owns 48,877 shares in the company, valued at $6,022,623.94. The disclosure for this sale can be found here. Over the last three months, insiders have sold 34,332 shares of company stock worth $4,258,182. Corporate insiders own 0.29% of the company’s stock.
ZTS has been the topic of a number of research analyst reports. ValuEngine lowered shares of Zoetis from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Goldman Sachs Group assumed coverage on shares of Zoetis in a report on Monday, September 9th. They issued a “conviction-buy” rating and a $145.00 price target on the stock. Credit Suisse Group set a $138.00 price target on shares of Zoetis and gave the company a “buy” rating in a report on Friday, October 11th. SunTrust Banks upped their price target on shares of Zoetis from $120.00 to $130.00 and gave the company a “hold” rating in a report on Tuesday, August 13th. Finally, Stifel Nicolaus set a $140.00 price target on shares of Zoetis and gave the company a “buy” rating in a report on Friday, September 13th. Eight investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $126.75.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Further Reading: Should I follow buy, hold and sell recommendations?
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.